

Patient: TEST PATIENT
Patient ID: **MDT022-283216**
Patient DOB: **9/9/1982**
Patient Age: **41**
Patient Sex: **Female**

Specimen: **Swab**
Collected: **8/12/24 9:00 AM PDT**
Received: **8/12/24 9:45 PM PDT**
Reported: **8/14/24 7:43 AM PDT**

Specimen ID: **2416758**
Provider: **Test Provider**
Account: **6518**
Facility: **Innovative Health Diagnos**

Molecular Report

Powered by Eden Software Solutions

+ POSITIVE SUMMARY

Pathogens **Atopobium vaginae, Gardnerella vaginalis, Lactobacillus gasseri, Lactobacillus iners, Ureaplasma Parvum, Ureaplasma urealyticum**

LEGEND

SANFORD GUIDE



Every effort is made to ensure the accuracy of Sanford Guide content. However, current full prescribing information available in the package insert for each drug should be consulted before prescribing any product. The editors and publisher are not responsible for errors or omissions or for any consequences, such as injury, damage, or death, from application of our print and digital content, and make no warranty, express or implied, with respect to the currency, accuracy, or completeness of the contents of this publication. Application of this information in a particular situation remains solely the professional responsibility of the clinician.

The data provided are intended to serve as a general guide to antibacterial usefulness based on package insert, treatment guidelines, published reports, in vitro activity, predominant patterns of susceptibility or resistance and/or demonstrated clinical effectiveness. Variability in resistance patterns due to local or regional differences or as a consequence of clinical setting, e.g., community onset vs. ICU-acquired infection, should be taken into account when using this information because the activity of antimicrobial agents can differ significantly and hence is beyond the scope of this general summary. Susceptibility testing results and your local antibiogram should be consulted in every case.

- [1] Preferred:** Agent is a first line therapy: reliably active in vitro, clinically effective, guideline recommended, recommended as a first-line agent or acceptable alternative agent in the Sanford Guide.
- [2] Alternative:** Agent is a potential alternative agent (active in vitro, possesses class activity comparable to known effective agents or a therapeutically interchangeable agents and hence likely to be clinically effective, but second line due to overly broad spectrum, toxicity, limited clinical experience, or paucity of direct evidence of effectiveness).
- [3] Limited Utility:** Limited utility such that the agent, although clinically effective in some settings or types of infections is not reliably effective in others, or should be used in combination with another agent, and/or its efficacy is limited by resistance which has been associated with treatment failure.

Atopobium vaginae	There is no recommendation data for this pathogen. Check below for additional information.
Gardnerella vaginalis	There is no recommendation data for this pathogen. Check below for additional information.
Lactobacillus gasseri	There is no recommendation data for this pathogen. Check below for additional information.
Lactobacillus iners	There is no recommendation data for this pathogen. Check below for additional information.
Ureaplasma urealyticum	There is no recommendation data for this pathogen. Check below for additional information.
Ureaplasma Parvum	There is no recommendation data for this pathogen. Check below for additional information.

Sanford Guide Content accessed on 8/14/24 7:43 AM PDT. For information about treatment and prescribing options, please log in at <https://lab.edenss.com/>.

Patient: TEST PATIENT
Patient ID: **MDT022-283216**
Patient DOB: **9/9/1982**
Patient Age: **41**
Patient Sex: **Female**

Specimen: **Swab**
Collected: **8/12/24 9:00 AM PDT**
Received: **8/12/24 9:45 PM PDT**
Reported: **8/14/24 7:43 AM PDT**

Specimen ID: **2416758**
Provider: **Test Provider**
Account: **6518**
Facility: **Innovative Health Diagnos**

Powered by **Eden Software Solutions**

Vaginitis Panel, Comprehensive Plus (AssureSwab)		
Test	Result	Range
Bacteria		
Atopobium vaginae	✓ Detected	Not Detected
Bacteroides fragilis	Not Detected	Not Detected
BVAB2	Not Detected	Not Detected
Chlamydia trachomatis	Not Detected	Not Detected
Enterococcus faecalis	Not Detected	Not Detected
Escherichia coli	Not Detected	Not Detected
Gardnerella vaginalis	✓ Detected	Not Detected
Haemophilus ducreyi	Not Detected	Not Detected
HSV-1	Not Detected	Not Detected
HSV-2	Not Detected	Not Detected
Lactobacillus crispatus	Detected	Detected
Lactobacillus gasseri	✓ Not Detected	Detected
Lactobacillus iners	✓ Not Detected	Detected
Lactobacillus jensenii	Detected	Detected
Megasphaera 1	Not Detected	Not Detected
Megasphaera 2	Not Detected	Not Detected
Mobiluncus curtisi	Not Detected	Not Detected
Mobiluncus mulieris	Not Detected	Not Detected
Mycoplasma genitalium	Not Detected	Not Detected
Mycoplasma hominis	Not Detected	Not Detected
Neisseria gonorrhoeae	Not Detected	Not Detected
Prevotella bivia	Not Detected	Not Detected
Staphylococcus aureus	Not Detected	Not Detected
Streptococcus agalactiae (GBS)	Not Detected	Not Detected
Treponema pallidum	Not Detected	Not Detected
Trichomoniasis vaginalis	Not Detected	Not Detected
Ureaplasma Parvum	✓ Detected	Not Detected
Ureaplasma urealyticum	✓ Detected	Not Detected
Fungi		
Candida albicans	Not Detected	Not Detected
Candida dubliniensis	Not Detected	Not Detected
Candida glabrata	Not Detected	Not Detected



Innovative Health Diagnostics
1565 McGaw Ave. Suite A
Irvine, CA 92614-5670
Phone Number: (949) 491-8080
CLIA: 05D2040304

Patient: TEST PATIENT
Patient ID: **MDT022-283216**
Patient DOB: **9/9/1982**
Patient Age: **41**
Patient Sex: **Female**

Specimen: **Swab**
Collected: **8/12/24 9:00 AM PDT**
Received: **8/12/24 9:45 PM PDT**
Reported: **8/14/24 7:43 AM PDT**

Specimen ID: **2416758**
Provider: **Test Provider**
Account: **6518**
Facility: **Innovative Health Diagnos**

Fungi		
Candida krusei	Not Detected	Not Detected
Candida lusitanae	Not Detected	Not Detected
Candida parapsilosis	Not Detected	Not Detected
Candida tropicalis	Not Detected	Not Detected

These tests are Lab Developed Tests and were developed, and its performance characteristics determined by Innovative Health Diagnostics. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used solely for clinical diagnosis or patient management decisions.

Comments:

No comments.

Patient: TEST PATIENT
Patient ID: **MDT022-283216**
Patient DOB: **9/9/1982**
Patient Age: **41**
Patient Sex: **Female**

Specimen: **Swab**
Collected: **8/12/24 9:00 AM PDT**
Received: **8/12/24 9:45 PM PDT**
Reported: **8/14/24 7:43 AM PDT**

Specimen ID: **2416758**
Provider: **Test Provider**
Account: **6518**
Facility: **Innovative Health Diagnos**

Molecular Report

Powered by **Eden Software Solutions**

Detected Pathogen - *Atopobium vaginae*

No Sanford Guide information is available for this pathogen. Sanford Guide coverage focuses on clinically relevant pathogens that may be of concern in making decisions concerning treatment of infections resulting from specific organisms or syndromes. Sanford Guide is not a repository for all data for all bacteria. Bacterial species that have uncertain therapeutic implications, e.g., likely colonizers or contaminants, are beyond the scope of, and hence are omitted from, Sanford Guide coverage.

Sanford Guide Content accessed on 8/14/24 7:43 AM PDT and truncated by Innovative Health Diagnostics.

VIEW FULL PATHOGEN ARTICLE HERE

For information about treatment and prescribing options, please log in at <https://lab.edenss.com/> | Powered by **Eden Software Solutions**

Detected Pathogen - *Gardnerella vaginalis*



Every effort is made to ensure the accuracy of Sanford Guide content. However, current full prescribing information available in the package insert for each drug should be consulted before prescribing any product. The editors and publisher are not responsible for errors or omissions or for any consequences, such as injury, damage, or death, from application of our print and digital content, and make no warranty, express or implied, with respect to the currency, accuracy, or completeness of the contents of this publication. Application of this information in a particular situation remains solely the professional responsibility of the clinician.

The data provided are intended to serve as a general guide to antibacterial usefulness based on package insert, treatment guidelines, published reports, in vitro activity, predominant patterns of susceptibility or resistance and/or demonstrated clinical effectiveness. Variability in resistance patterns due to local or regional differences or as a consequence of clinical setting, e.g., community onset vs. ICU-acquired infection, should be taken into account when using this information because the activity of antimicrobial agents can differ significantly and hence is beyond the scope of this general summary. Susceptibility testing results and your local antibiogram should be consulted in every case.

Clinical Setting

- Sexually active female (typically) with complaints of malodorous vaginal discharge (see [bacterial vaginosis](#)).
 - Mild to moderate grayish vaginal discharge with a fishy odor. pH >4.5
 - Absence of vaginal inflammation on exam.
 - Itching and irritation are minimal or absent.
- Wet mount of vaginal discharge shows "clue" cells, vaginal epithelial cells with numerous adherent coccobacilli; presence of numerous polys suggestive of coexisting infection.

Sanford Guide Content accessed on 8/14/24 7:43 AM PDT and truncated by Innovative Health Diagnostics.

VIEW FULL PATHOGEN ARTICLE HERE

For information about treatment and prescribing options, please log in at <https://lab.edenss.com/> | Powered by **Eden Software Solutions**

Detected Pathogen - *Lactobacillus gasseri*



Every effort is made to ensure the accuracy of Sanford Guide content. However, current full prescribing information available in the package insert for each drug should be consulted before prescribing any product. The editors and publisher are not responsible for errors or omissions or for any consequences, such as injury, damage, or death, from application of our print and digital content, and make no warranty, express or implied, with respect to the currency, accuracy, or completeness of the contents of this publication. Application of this information in a particular situation remains solely the professional responsibility of the clinician.

The data provided are intended to serve as a general guide to antibacterial usefulness based on package insert, treatment guidelines, published reports, in vitro activity, predominant patterns of susceptibility or resistance and/or demonstrated clinical effectiveness. Variability in resistance patterns due to local or regional differences or as a

Patient: TEST PATIENT
Patient ID: **MDT022-283216**
Patient DOB: **9/9/1982**
Patient Age: **41**
Patient Sex: **Female**

Specimen: **Swab**
Collected: **8/12/24 9:00 AM PDT**
Received: **8/12/24 9:45 PM PDT**
Reported: **8/14/24 7:43 AM PDT**

Specimen ID: **2416758**
Provider: **Test Provider**
Account: **6518**
Facility: **Innovative Health Diagnos**

Consequence of clinical setting, e.g., community onset vs. ICU-acquired infection, should be taken into account when using this information because the activity of antimicrobial agents can differ significantly and hence is beyond the scope of this general summary. Susceptibility testing results and your local antibiogram should be consulted in every case.

Clinical Setting

- Positive blood culture in patient with an IV line.
- Immunocompromised hosts.
- Specific therapy.
- Removal of infected IV line is primary therapy.

Sanford Guide Content accessed on 8/14/24 7:43 AM PDT and truncated by Innovative Health Diagnostics.

VIEW FULL PATHOGEN ARTICLE [HERE](#)

For information about treatment and prescribing options, please log in at <https://lab.edenss.com/> | Powered by **Eden Software Solutions**

Detected Pathogen - Lactobacillus iners

SANFORD GUIDE



Every effort is made to ensure the accuracy of Sanford Guide content. However, current full prescribing information available in the package insert for each drug should be consulted before prescribing any product. The editors and publisher are not responsible for errors or omissions or for any consequences, such as injury, damage, or death, from application of our print and digital content, and make no warranty, express or implied, with respect to the currency, accuracy, or completeness of the contents of this publication. Application of this information in a particular situation remains solely the professional responsibility of the clinician.

The data provided are intended to serve as a general guide to antibacterial usefulness based on package insert, treatment guidelines, published reports, in vitro activity, predominant patterns of susceptibility or resistance and/or demonstrated clinical effectiveness. Variability in resistance patterns due to local or regional differences or as a consequence of clinical setting, e.g., community onset vs. ICU-acquired infection, should be taken into account when using this information because the activity of antimicrobial agents can differ significantly and hence is beyond the scope of this general summary. Susceptibility testing results and your local antibiogram should be consulted in every case.

Clinical Setting

- Positive blood culture in patient with an IV line.
- Immunocompromised hosts.
- Specific therapy.
- Removal of infected IV line is primary therapy.

Sanford Guide Content accessed on 8/14/24 7:43 AM PDT and truncated by Innovative Health Diagnostics.

VIEW FULL PATHOGEN ARTICLE [HERE](#)

For information about treatment and prescribing options, please log in at <https://lab.edenss.com/> | Powered by **Eden Software Solutions**

Detected Pathogen - Ureaplasma urealyticum

SANFORD GUIDE



Every effort is made to ensure the accuracy of Sanford Guide content. However, current full prescribing information available in the package insert for each drug should be consulted before prescribing any product. The editors and publisher are not responsible for errors or omissions or for any consequences, such as injury, damage, or death, from application of our print and digital content, and make no warranty, express or implied, with respect to the currency, accuracy, or completeness of the contents of this publication. Application of this information in a particular situation remains solely the professional responsibility of the clinician.

The data provided are intended to serve as a general guide to antibacterial usefulness based on package insert, treatment guidelines, published reports, in vitro activity, predominant patterns of susceptibility or resistance and/or demonstrated clinical effectiveness. Variability in resistance patterns due to local or regional differences or as a consequence of clinical setting, e.g., community onset vs. ICU-acquired infection, should be taken into account when using this information because the activity of antimicrobial agents can differ significantly and hence is beyond the scope of this general summary. Susceptibility testing results and your local antibiogram should be consulted in every case.

Patient: TEST PATIENT
Patient ID: **MDT022-283216**
Patient DOB: **9/9/1982**
Patient Age: **41**
Patient Sex: **Female**

Specimen: **Swab**
Collected: **8/12/24 9:00 AM PDT**
Received: **8/12/24 9:45 PM PDT**
Reported: **8/14/24 7:43 AM PDT**

Specimen ID: **2416758**
Provider: **Test Provider**
Account: **6518**
Facility: **Innovative Health Diagnos**

Clinical Setting

- Colonizers or possibly pathogenic organisms of lower genital tract.
- May be associated with *Mycoplasma hominis* or *Mycoplasma genitalium*
- Transmitted between individuals by sexual contact or vertically.
- Controversial amongst experts when pathogenic vs colonizing, but most would treat if symptomatic.
- Associated with non-gonococcal urethritis in men and genital tract infections in women.
- Seen neonatal sepsis, meningitis and pneumonia syndromes.

- Like *Mycoplasma* species can be pathogenic in immunosuppressed individuals, particularly those with antibody deficiencies, after organ transplant, preterm infants.
- Clinical syndromes associated include genito-urinary infections, arthritis, osteomyelitis, preterm labor or chorioamnionitis, bacteremia, pneumonia, meningitis, endocarditis, abscess.
- Associated with hyperammonemia syndrome (see comments) in immunocompromised individuals, particularly after lung transplant (*Curr Opin Infect Dis* 35:262 2022 *Clin Transplant* 35:e14334 2021)

Diagnosis

Sanford Guide Content accessed on 8/14/24 7:43 AM PDT and truncated by Innovative Health Diagnostics.

VIEW FULL PATHOGEN ARTICLE [HERE](#)

For information about treatment and prescribing options, please log in at <https://lab.edenss.com/> | Powered by **Eden Software Solutions**

Detected Pathogen - Ureaplasma Parvum

SANFORD GUIDE



Every effort is made to ensure the accuracy of Sanford Guide content. However, current full prescribing information available in the package insert for each drug should be consulted before prescribing any product. The editors and publisher are not responsible for errors or omissions or for any consequences, such as injury, damage, or death, from application of our print and digital content, and make no warranty, express or implied, with respect to the currency, accuracy, or completeness of the contents of this publication. Application of this information in a particular situation remains solely the professional responsibility of the clinician.

The data provided are intended to serve as a general guide to antibacterial usefulness based on package insert, treatment guidelines, published reports, in vitro activity, predominant patterns of susceptibility or resistance and/or demonstrated clinical effectiveness. Variability in resistance patterns due to local or regional differences or as a consequence of clinical setting, e.g., community onset vs. ICU-acquired infection, should be taken into account when using this information because the activity of antimicrobial agents can differ significantly and hence is beyond the scope of this general summary. Susceptibility testing results and your local antibiogram should be consulted in every case.

Clinical Setting

- Colonizers or possibly pathogenic organisms of lower genital tract.
- May be associated with *Mycoplasma hominis* or *Mycoplasma genitalium*
- Transmitted between individuals by sexual contact or vertically.
- Controversial amongst experts when pathogenic vs colonizing, but most would treat if symptomatic.
- Associated with non-gonococcal urethritis in men and genital tract infections in women.
- Seen neonatal sepsis, meningitis and pneumonia syndromes.

- Like *Mycoplasma* species can be pathogenic in immunosuppressed individuals, particularly those with antibody deficiencies, after organ transplant, preterm infants.
- Clinical syndromes associated include genito-urinary infections, arthritis, osteomyelitis, preterm labor or chorioamnionitis, bacteremia, pneumonia, meningitis, endocarditis, abscess.
- Associated with hyperammonemia syndrome (see comments) in immunocompromised individuals, particularly after lung transplant (*Curr Opin Infect Dis* 35:262 2022 *Clin Transplant* 35:e14334 2021)

Diagnosis

Sanford Guide Content accessed on 8/14/24 7:43 AM PDT and truncated by Innovative Health Diagnostics.



Innovative Health Diagnostics
1565 McGaw Ave. Suite A
Irvine, CA 92614-5670
Phone Number: (949) 491-8080
CLIA: 05D2040304

Patient: TEST PATIENT
Patient ID: **MDT022-283216**
Patient DOB: **9/9/1982**
Patient Age: **41**
Patient Sex: **Female**

Specimen: **Swab**
Collected: **8/12/24 9:00 AM PDT**
Received: **8/12/24 9:45 PM PDT**
Reported: **8/14/24 7:43 AM PDT**

Specimen ID: **2416758**
Provider: **Test Provider**
Account: **6518**
Facility: **Innovative Health Diagnos**

[VIEW FULL PATHOGEN ARTICLE HERE](#)

For information about treatment and prescribing options, please log in at <https://lab.edenss.com/> | Powered by **Eden Software Solutions**